NR4A1 and breast cancer: This is supported by a 5-year survival rate of 85% for individuals diagnosed with stage I breast cancer, which contrasts significantly with the 94% to 99% survival rates reported for hormone receptor-positive and ERBB2-positive patient cohorts.